Close
Novotech
Jabsco PureFlo 21 Single Use

Clinical Trials

Cmed to Demonstrate how encapsia® Transforms Clinical Trial Data Management, Capture and Reporting at Leading Oncology Meetings

Cmed, an oncology focused, innovative technology-led CRO, announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual...

Direct-to-Patient Solutions Assuring Patient Participation and Retention in Clinical Trials

The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just...

Cmed to Showcase Advanced Data Insights and Analytics Capabilities of encapsia® Clinical Data Suite at Partnerships in Clinical Trials Europe

Cmed, an innovative technology-led CRO, will demonstrate its encapsia® clinical data suite at Partnerships in Clinical Trials Europe, taking place 28-29 November 2017 in Amsterdam, The Netherlands. Currently used in trials with nine Pharma companies, including...

Asia’s increasing levels of clinical trial industry competition are to your benefit

Biotechnology and pharmaceutical companies within the United States and Europe face an increasing number of hurdles when undertaking clinical trials within their own country or region; problems such as over saturated patient pools, difficulties meeting and maintaining enrollment numbers, increasing costs and lengthy time delays. While clinical trials...

New centre is tackling manufacturing challenge of cell therapy field

Stem cell science has made huge progress since the early 1960s when Canadian researchers James Till and Ernest McCulloch discovered blood stem cells and advanced medical research across the globe. Today, the Alliance for Regenerative Medicine estimates there are more...

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

Hutchison China MediTech Limited reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor of vascular endothelial growth factor receptor given in combination with Iressa®. These data were from an ongoing Phase...

MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris

MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%)...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »